Description
Benitec Biopharma Limited, a biotechnology company, develops treatments for chronic and life-threatening human diseases based on its gene silencing therapy, DNA-directed RNA interference (ddRNAi) in Australia and the United States. The company provides BB-301, a single administration ddRNAi-based gene therapy for the treatment of oculopharyngeal muscular dystrophy; and BB-103 ddRNAi-based therapies for the treatment of human hepatitis B. The company was founded in 1995 and is headquartered in Melbourne, Australia.
